Nachrichten zur Astellas Pharma, Inc. Aktie

Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

TOKYO and SAN FRANCISCO , Sept. 20, 2019 /PRNewswire/ --…

Seattle Genetics Enfortumab Vedotin BLA Gets Priority Review

The FDA accepts Seattle Genetics (SGEN) and Astellas BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial…

Astellas joins US startup to create tiny diagnostic implants

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...…

Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

BOTHELL, Wash. and TOKYO , Sept. 16, 2019 /PRNewswire/ --…

Astellas Partners with MBC BioLabs to Help Pioneering Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts

MENLO PARK, Calif. , Sept. 11, 2019 /PRNewswire/ -- Astellas Venture Management, LLC (President: …

Johnson & Johnsons $3.5 Billion Prostate Cancer Drug Sales At Risk-

Johnson & Johnson (NYSE:JNJ) is the leader in the prostate cancer hormonal therapy market, with Zytiga sales of $3.5 billion…

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

TOKYO and NEW YORK , Aug. 21, 2019 /PRNewswire/ -- Astellas…

Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

TOKYO , Aug. 6, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: …

Astellas signs licensing deal for Frequencys regenerative drug FX-322

As per the agreement terms, Astellas will undertake the development and commercialisation of FX-322 outside of the US, while Frequency…

Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

TOKYO and BOTHELL, Wash. , July 16, 2019 /PRNewswire/ -- …

Aevi Genomic Medicine Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor

PHILADELPHIA , July 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi")…

Astellas Appoints Chelsea Glinski as National Vice President Oncology Sales

NORTHBROOK, Ill. , July 10, 2019 /PRNewswire/ -- Astellas today announced that Chelsea…

Seattle Genetics, Astellas Cancer Candidate Attains 44% ORR

Seattle Genetics (SGEN) and Astellas post favorable data from the first cohort of a phase II study on enfortumab vedotin…

UPDATE 1-Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder…

CORRECTED-Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder…

Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder…

UPDATE 3-Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe

Two drugmakers will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients out-of-pocket drug costs as…

UPDATE 2-Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe

Two drugmakers will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients out-of-pocket drug costs as…

Drugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probe

Two drugmakers will pay nearly $125 million to settle claims they used charities that help cover Medicare patients out-of-pocket drug…

UPDATE 1-Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe

Two drugmakers will pay nearly $125 million to settle claims they used charities that help cover Medicare patients out-of-pocket drug costs as…

Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe

Two drugmakers will pay nearly $125 million to settle claims they used charities that help cover Medicare patients out-of-pocket drug costs as…

Astellas Announces Key Senior Leadership Promotions and New Hire in Medical and Development Organization

NORTHBROOK, Ill. , April 3, 2019 /PRNewswire/ -- Astellas is pleased to announce two recent…

Xencor, Astellas Pharma collaborate on novel bispecific antibody program

As part of a research and license agreement, Astellas Pharma will be able to use Xencors bispecific technology to advance…

Seattle Genetics, Astellas Report Positive Cancer Study Data

Seattle Genetics (SGEN) and partner Astellas present positive top-line data from the first cohort of a phase II study on…

Actinium Successfully Completes Second Module of Collaborative Research Program with Astellas; Third Module Initiated

NEW YORK , March 29, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. …

Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

BOTHELL, Wash. and TOKYO , March 28, 2019 /PRNewswire/ -- …

DIVIDEND/INTEREST INFORMATION - 27.03.2019 - 1

FOLGENDE WERTPAPIERE WERDEN AM 26.03.2019 CUM DIVIDENDE/ZINSEN UND AM 27.03.2019 EX DIVIDENDE/ZINSEN GEHANDELT. THE PRE-DIVIDEND/INTEREST DAY OF THE FOLLOWING SHARES WILL…

Astellas Pharma (ALPMF) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas, Pfizers XTANDI meets endpoint in phase 3 prostate cancer trial

The preliminary safety analysis of the ARCHES trial appears consistent with the safety profile of XTANDI in previous clinical trials…

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer

TOKYO and NEW YORK , Dec. 20, 2018 /PRNewswire/ --…

Cresemba - Basilea erhält Meilensteinzahlung für Anti-Pilz-Wirkstoff

Basilea erhält Meilensteinzahlungen in der Höhe von 10 Millionen Franken für das Medikament Cresemba von Astellas Pharma....…

Cancer Research Highlight: Astellas Takes Us Into A New Generation Of Therapy For AML

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 2-Astellas Pharma gets U.S. nod for blood cancer treatment

The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japans Astellas Pharma Inc, making it the first…

UPDATE 1-Astellas Pharma gets U.S. nod for blood cancer treatment

Japans Astellas Pharma Inc on Wednesday received approval from the U.S. Food and Drug Administration for its blood cancer treatment, according to…

Astellas Pharma gets U.S. nod for blood cancer treatment

Japans Astellas Pharma Inc on Wednesday received approval from the U.S. Food and Drug Administration for its blood cancer treatment, according to…

Astellas Global Health Foundation Launches

TOKYO and NORTHBROOK, Ill. , Nov. 20, 2018 /PRNewswire/ -- Astellas…

Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting

TOKYO , Nov. 19, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and…

Anaeropharma Science unterzeichnet gemeinsame Forschungsvereinbarung mit Astellas zur Entwicklung neuartiger Anti-Tumor-Medikamente auf Grundlage von Bifidobacterium

Anaeropharma Science, Inc.: Tokio (ots/PRNewswire) - Wie Anaeropharma Science Inc. mit Sitz in Tokio (nachfolgend "Anaeropharma") am 25. September bekanntgab,…

DIVIDEND/INTEREST INFORMATION - 26.09.2018 - 1

FOLGENDE WERTPAPIERE WERDEN AM 25.09.2018 CUM DIVIDENDE/ZINSEN UND AM 26.09.2018 EX DIVIDENDE/ZINSEN GEHANDELT. THE PRE-DIVIDEND/INTEREST DAY OF THE FOLLOWING SHARES WILL…

Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

TOKYO and CHERTSEY, England , Sept. 24, 2018 /PRNewswire/ --…

Pfizer Amends Xtandi Study Protocols to Speed Up Completion

Pfizer (PFE) and Astellas Pharma announce amendment of protocols for two phase III studies evaluating Xtandi in hormone-sensitive prostate cancer,…

Pfizer, Astellas amend clinical research protocols for two phase 3 trials of Enzalutamide

These amendments accelerate timelines for the anticipated primary completion dates of both trials. ARCHES is a randomized Phase 3 study…

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi…

Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer

NEW YORK and TOKYO , Aug. 22, 2018 /PRNewswire/ --…